| The ancient evolutionary history of polyomaviruses CB Buck, K Van Doorslaer, A Peretti, EM Geoghegan, MJ Tisza, P An, ... PLoS pathogens 12 (4), e1005574, 2016 | 228 | 2016 |
| Characterization of BK polyomaviruses from kidney transplant recipients suggests a role for APOBEC3 in driving in-host virus evolution A Peretti, EM Geoghegan, DV Pastrana, S Smola, P Feld, M Sauter, ... Cell host & microbe 23 (5), 628-635. e7, 2018 | 75 | 2018 |
| Infectious entry and neutralization of pathogenic JC polyomaviruses EM Geoghegan, DV Pastrana, RM Schowalter, U Ray, W Gao, M Ho, ... Cell reports 21 (5), 1169-1179, 2017 | 58 | 2017 |
| Surface (S) Layer Proteins of Lactobacillus acidophilus Block Virus Infection via DC-SIGN Interaction M Prado Acosta, EM Geoghegan, B Lepenies, S Ruzal, M Kielian, ... Frontiers in microbiology 10, 810, 2019 | 54 | 2019 |
| 225Ac‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models R Garg, KJH Allen, W Dawicki, EM Geoghegan, DL Ludwig, E Dadachova Cancer Medicine 10 (3), 1128-1140, 2021 | 38 | 2021 |
| Antiviral activity of a single-domain antibody immunotoxin binding to glycoprotein D of herpes simplex virus 2 EM Geoghegan, H Zhang, PJ Desai, A Biragyn, RB Markham Antimicrobial agents and chemotherapy 59 (1), 527-535, 2015 | 27 | 2015 |
| Preclinical development of an Actinium-225-Labeled antibody radio-conjugate directed against CD45 for targeted conditioning and radioimmunotherapy DL Ludwig, RA Bryan, W Dawicki, EM Geoghegan, Q Liang, M Gokhale, ... Biology of Blood and Marrow Transplantation 26 (3), S160-S161, 2020 | 10 | 2020 |
| Infectious entry and neutralization of pathogenic JC polyomaviruses. Cell Rep 21: 1169–1179 EM Geoghegan, DV Pastrana, RM Schowalter, U Ray, W Gao, M Ho, ... | 10 | 2017 |
| Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy W Dawicki, KJH Allen, R Garg, EM Geoghegan, MS Berger, DL Ludwig, ... Oncotarget 11 (39), 3571, 2020 | 7 | 2020 |
| Sierra clinical trial dosimetry results support low dose anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for targeted lymphodepletion prior to adoptive cell therapy R Nath, EM Geoghegan, ML Ulrickson, JA Spross, RH Lichtenstein, ... Blood 134, 1958, 2019 | 4 | 2019 |
| 225Ac-CD33 Radioimmunotherapy potently increases the sensitivity of resistant acute myeloid leukemia lines to the Bcl-2 inhibitor venetoclax by mediating a … R Garg, E Geoghegan, KJ Allen, W Dawicki, E Dadachova, DL Ludwig Cancer Research 79 (13_Supplement), 3808-3808, 2019 | 2 | 2019 |
| Identification of a Second Raccoon-Associated Polyomavirus EM Geoghegan, NL Welch, MJ Yabsley, ME Church, PA Pesavento, ... Genome announcements 5 (26), 10.1128/genomea. 00548-17, 2017 | 2 | 2017 |
| Radioimmunoconjugates directed to nkg2d ligands for the treatment of cancer DL Ludwig, E Geoghegan, S Seth, J Hwang, P Diamond US Patent App. 18/557,988, 2024 | 1 | 2024 |
| Antibody radioconjugates in combination with CD47 immunotherapy improves antitumor efficacy in preclinical models of solid tumors J Li, M McCloskey, C Jennings, S Pachhal, E Greer, A Chin, ... Journal of Nuclear Medicine 63 (supplement 2), 2574-2574, 2022 | 1 | 2022 |
| Her3 radioimmunotherapy for the treatment of solid cancers DL Ludwig, E Geoghegan, S Seth, P Diamond US Patent App. 17/532,919, 2022 | 1 | 2022 |
| Iomab with Adoptive Cellular Therapy (Iomab-ACT): A Pilot Study of 131-I Apamistamab Followed By CD19-Targeted CAR T-Cell Therapy for Patients with Relapsed or Refractory B … MB Geyer, B Cadzin, E Halton, P Kane, B Senechal, EM Geoghegan, ... Blood 138, 4810, 2021 | 1 | 2021 |
| Preclinical development of an Actinium-225-labeled antibody radio-conjugate directed against CD45 for targeted conditioning and radioimmunotherapy D Ludwig, R Bryan, W Dawicki, EM Geoghegan, Q Liang, S Seth, ... Blood 134, 5601, 2019 | 1 | 2019 |
| Identification and Applications of Llama-Derived Single Domain Antibodies Binding to Glycoprotein D of Herpes Simplex Virus 2 EM Geoghegan Johns Hopkins University, 2013 | 1 | 2013 |
| RADIOIMMUNOCONJUGATES TARGETING GRP78 FOR USE IN THE TREATMENT OF CANCER DL Ludwig, E Geoghegan, H Kotanides, S Seth US Patent App. 18/696,453, 2024 | | 2024 |
| Trophoblast glycoprotein radioimmunotherapy for the treatment of solid cancers DL Ludwig, E Geoghegan US Patent App. 18/025,849, 2023 | | 2023 |
